Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial - ScienceDirect
Role of chemotherapy in carcinoma stomach | PPT
XELOX May Improve Survival in Gastric Cancer - CancerConnect
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in ...
The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study | Gastric Cancer
Towards Personalization in the Curative Treatment of Gastric Cancer. - Abstract - Europe PMC
Complete mesogastric excision for locally advanced gastric cancer: short-term outcomes of a randomized clinical trial: Cell Reports Medicine
Frontiers | VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2 ...
PPT - Adjuvant Therapy for Carcinoma of Stomach PowerPoint Presentation - ID:9701764
Is adjuvant chemotherapy necessary for early gastric cancer? | Cancer Biology & Medicine
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial - ScienceDirect
The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study | Gastric Cancer
Cancers | Free Full-Text | Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN)
Early stage gastric adenocarcinoma: clinical and molecular landscapes | Nature Reviews Clinical Oncology
ADJUVANT CAPECITABINE AND OXALIPLATIN FOR GASTRIC CANCER AFTER D2 GASTRECTOMY (CLASSIC): A PHASE 3 OPEN-LABEL,RANDOMISED CONTROLLED TRIAL Yung-Jue Bang*, - ppt download
Practice-changing Evidence in Treatment of Noncolorectal GI Cancers - The ASCO Post
ADJUVANT CAPECITABINE AND OXALIPLATIN FOR GASTRIC CANCER AFTER D2 GASTRECTOMY (CLASSIC): A PHASE 3 OPEN-LABEL,RANDOMISED CONTROLLED TRIAL Yung-Jue Bang*, - ppt download
JGC :: Journal of Gastric Cancer
Clinical biomarkers in adjuvant chemotherapy for gastric cancer after D2 dissection by a pooled analysis of individual patient data from large randomized controlled trials | Gastric Cancer
Chemotherapy Options for Gastric Cancer | PPT
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. | Semantic Scholar
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial - ScienceDirect
Discussion Gastric Cancer LBA 4002, abstracts 4003, ppt download
Prognostic impact of PD-L1 expression in gastric cancer according to... | Download Scientific Diagram
